Figure 2From: Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation Transfusions and anti-HBs levels in one patient who was temporarily switched to commercial HBIG and then back to HIP. Between October 1998 and September 2000 this patient received commercial HBIG due to logistic reasons (lived temporarily far away from a transfusion center providing HIP).Back to article page